title: Tolvaptan.
abstract: In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
authors: Harper University Hospital, 3990 John R Street, 9 Webber Core, Detroit, MI 48201, USA. JGhali@dmc.org
authors: Jalal K
authors: JK
authors: Ghali
authors: Bashar
authors: B
authors: Hamad
authors: Uma
authors: U
authors: Yasothan
authors: Peter
authors: P
authors: Kirkpatrick
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy* / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D000077602:Tolvaptan
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000077602:Tolvaptan